ECSP15014138A - Etanercept correctamente plegado de alta pureza y excelente rendimiento - Google Patents
Etanercept correctamente plegado de alta pureza y excelente rendimientoInfo
- Publication number
- ECSP15014138A ECSP15014138A ECIEPI201514138A ECPI201514138A ECSP15014138A EC SP15014138 A ECSP15014138 A EC SP15014138A EC IEPI201514138 A ECIEPI201514138 A EC IEPI201514138A EC PI201514138 A ECPI201514138 A EC PI201514138A EC SP15014138 A ECSP15014138 A EC SP15014138A
- Authority
- EC
- Ecuador
- Prior art keywords
- high purity
- etanercept
- folded
- preparations
- folded etanercept
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/165—Extraction; Separation; Purification by chromatography mixed-mode chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Abstract
Método de cromatografía de modo mixto para separar las conformaciones correctamente plegadas de las incorrectamente plegadas de una proteína dada. El método es muy eficaz en la separación de etanercept correctamente plegado del etanercept incorrectamente plegado y de agregados con rendimientos comercialmente atractivos que permiten obtener preparaciones de etanercept de una muy alta pureza en términos de etanercept correctamente plegado versus etanercept incorrectamente plegado. La invención está dirigida además a preparaciones de proteínas y formulaciones que comprenden proteínas correctamente plegadas obtenidas usando los métodos de la presente, y métodos de tratamiento que emplean las preparaciones de gran pureza obtenidas del método de modo mixto.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261699552P | 2012-09-11 | 2012-09-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP15014138A true ECSP15014138A (es) | 2016-01-29 |
Family
ID=50233493
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECIEPI201514138A ECSP15014138A (es) | 2012-09-11 | 2015-04-10 | Etanercept correctamente plegado de alta pureza y excelente rendimiento |
Country Status (33)
| Country | Link |
|---|---|
| US (6) | US20140072560A1 (es) |
| EP (1) | EP2895188B1 (es) |
| JP (3) | JP2015533797A (es) |
| KR (2) | KR102250937B1 (es) |
| CN (2) | CN104902914B (es) |
| AR (1) | AR092532A1 (es) |
| AU (2) | AU2013315750B9 (es) |
| BR (1) | BR112015005161A2 (es) |
| CA (1) | CA2882551A1 (es) |
| CL (1) | CL2015000572A1 (es) |
| CO (1) | CO7400876A2 (es) |
| CY (1) | CY1120062T1 (es) |
| DK (1) | DK2895188T3 (es) |
| DO (1) | DOP2015000055A (es) |
| EA (1) | EA031324B1 (es) |
| EC (1) | ECSP15014138A (es) |
| ES (1) | ES2657377T3 (es) |
| HR (1) | HRP20180182T1 (es) |
| HU (1) | HUE036524T2 (es) |
| IL (2) | IL237311B (es) |
| IN (1) | IN2015KN00452A (es) |
| LT (1) | LT2895188T (es) |
| MX (2) | MX360044B (es) |
| NO (1) | NO2972131T3 (es) |
| PE (2) | PE20150996A1 (es) |
| PL (1) | PL2895188T3 (es) |
| PT (1) | PT2895188T (es) |
| RS (1) | RS57013B1 (es) |
| SG (1) | SG11201501460RA (es) |
| SI (1) | SI2895188T1 (es) |
| SM (1) | SMT201800163T1 (es) |
| TW (2) | TWI716649B (es) |
| WO (1) | WO2014043103A1 (es) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008543839A (ja) | 2005-06-14 | 2008-12-04 | アムジェン インコーポレーテッド | 自己緩衝タンパク質製剤 |
| AU2012326170B2 (en) | 2011-10-18 | 2016-12-22 | Coherus Biosciences, Inc. | Etanercept formulations stabilized with metal ions |
| US10485869B2 (en) | 2011-10-18 | 2019-11-26 | Coherus Biosciences, Inc. | Etanercept formulations stabilized with meglumine |
| KR102250937B1 (ko) * | 2012-09-11 | 2021-05-12 | 코히러스 바이오사이언시즈, 인코포레이티드 | 고순도 및 탁월한 수율의 정확하게 폴딩된 에타너셉트 |
| WO2015189832A1 (en) * | 2014-06-13 | 2015-12-17 | Lupin Limited | Process for the purification of tnfr:fc fusion protein |
| EP2975050B1 (en) | 2014-07-18 | 2019-05-29 | Sandoz Ag | Quantification of misfolded TNFR2:Fc |
| KR102018608B1 (ko) * | 2014-12-31 | 2019-09-06 | 주식회사 엘지화학 | 목적하는 함량으로 불순물을 포함하는 TNFR-Fc 융합 단백질의 제조방법 |
| US20180079796A1 (en) | 2015-03-13 | 2018-03-22 | Samsung Bioepis Co., Ltd. | Anti-tnf-alpha polypeptide composition and use thereof |
| CN108350026A (zh) * | 2015-11-18 | 2018-07-31 | 默克专利股份公司 | 离子交换色谱法中改进的蛋白质分离 |
| BR112018009882A2 (pt) * | 2015-11-18 | 2018-11-13 | Merck Patent Gmbh | gradientes de ph-sal opostos para separações melhoradas de proteína |
| CA3026518A1 (en) * | 2016-06-17 | 2017-12-21 | Genentech, Inc. | Purification of multispecific antibodies |
| ES3064802T3 (en) | 2016-10-21 | 2026-04-29 | Amgen Inc | Pharmaceutical formulations and methods of making the same |
| EP3824906A1 (en) | 2016-12-21 | 2021-05-26 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| MX2019011343A (es) * | 2017-03-24 | 2019-11-18 | Council Scient Ind Res | Un procedimiento para la purificacion de fragmentos de anticuerpos recombinantes. |
| CA3042126A1 (en) | 2018-05-03 | 2019-11-03 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Methods of treating kawasaki disease |
| CN112876567A (zh) * | 2019-11-29 | 2021-06-01 | 广东菲鹏制药股份有限公司 | Fc融合蛋白及其纯化方法 |
| AU2021262609A1 (en) | 2020-05-01 | 2022-12-22 | Kashiv Biosciences, Llc | An improved process of purification of protein |
| AU2022236913A1 (en) * | 2021-03-16 | 2023-10-26 | Kashiv Biosciences, Llc | Novel formulation of fusion protein |
| WO2022234412A1 (en) * | 2021-05-03 | 2022-11-10 | Lupin Limited | A process for purification of fc-fusion proteins |
| EP4421089A4 (en) * | 2021-10-19 | 2026-01-07 | Alteogen Inc | METHOD FOR PURIFYING A FUSION PROTEIN HAVING AN IGG FC DOMAIN |
| US20260159569A1 (en) * | 2024-12-06 | 2026-06-11 | Qilu Pharmaceutical Co., Ltd. | Variants of etanercept and related processes |
Family Cites Families (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5605690A (en) | 1989-09-05 | 1997-02-25 | Immunex Corporation | Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor |
| US5395760A (en) | 1989-09-05 | 1995-03-07 | Immunex Corporation | DNA encoding tumor necrosis factor-α and -β receptors |
| DE59010908D1 (de) | 1989-09-12 | 2000-08-10 | Hoffmann La Roche | TNF-bindende Proteine |
| IT1240314B (it) | 1989-09-28 | 1993-12-07 | Immunobiology Research Institutes, Inc. | Formulazioni acquose stabilizzate di piccoli peptidi. |
| EP0464533B1 (de) | 1990-06-28 | 1998-07-29 | Hoechst Aktiengesellschaft | Fusionsproteine mit immunglobulinanteilen, ihre Herstellung und Verwendung |
| NZ256293A (en) | 1992-09-15 | 1997-06-24 | Immunex Corp | Method of treating tumour necrosis factor - mediated inflammation by use of tnf antagonist |
| EP0852951A1 (de) | 1996-11-19 | 1998-07-15 | Roche Diagnostics GmbH | Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern |
| US7294481B1 (en) | 1999-01-05 | 2007-11-13 | Immunex Corporation | Method for producing recombinant proteins |
| US20010021380A1 (en) | 1999-04-19 | 2001-09-13 | Pluenneke John D. | Soluble tumor necrosis factor receptor treatment of medical disorders |
| US20040220103A1 (en) | 1999-04-19 | 2004-11-04 | Immunex Corporation | Soluble tumor necrosis factor receptor treatment of medical disorders |
| CA2366785C (en) | 1999-04-19 | 2012-02-07 | Immunex Corporation | Soluble tumor necrosis factor receptor treatment of medical disorders |
| BR0108193A (pt) | 2000-02-10 | 2003-02-25 | Wyeth Corp | Processo para tratamento ou inibição de dano celular ou morte celular |
| US8632778B2 (en) | 2000-08-11 | 2014-01-21 | Chugai Seiyaku Kabushiki Kaisha | Stabilized anti-interleukin-6 antibody-containing preparations |
| EE200300408A (et) | 2001-02-23 | 2003-12-15 | Immunex Corporation | Aktiivsete valkude saagise suurendamine |
| CA2476934C (en) * | 2002-02-27 | 2009-06-16 | Immunex Corporation | Stabilized tnfr-fc composition comprising arginine |
| DE60236025D1 (de) * | 2002-08-22 | 2010-05-27 | Vasopharm Biotech Gmbh | Pharmazeutische zusammensetzung enthaltend l-arginin |
| US20040115263A1 (en) | 2002-08-26 | 2004-06-17 | Robertson David W. | Use of bupropion for treating restless legs syndrome |
| EA009079B1 (ru) | 2003-02-28 | 2007-10-26 | Арес Трейдинг С.А. | Жидкие составы фактор некроза опухоли-связывающих белков |
| WO2004082715A1 (ja) | 2003-03-20 | 2004-09-30 | Eisai Co., Ltd. | 炎症性腸疾患治療剤としての併用医薬 |
| SG145712A1 (en) | 2003-08-01 | 2008-09-29 | Amgen Inc | Crystalline tumor necrosis factor receptor 2 polypeptides |
| WO2005037214A2 (en) | 2003-10-14 | 2005-04-28 | Intermune, Inc. | Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of hcv replication |
| KR101150050B1 (ko) * | 2004-02-27 | 2012-07-05 | 지이 헬스케어 바이오-사이언시스 에이비 | 항체 정제 방법 |
| JP5554466B2 (ja) | 2004-03-01 | 2014-07-23 | 味の素株式会社 | 抗ヒトＴＮＦ−α抗体活性低下抑制剤 |
| PL1720972T3 (pl) | 2004-03-05 | 2014-06-30 | Dpx Holdings Bv | Proces hodowli komórek poprzez ciągłą perfuzję i zmienny przepływ styczny |
| US20070196364A1 (en) | 2004-07-27 | 2007-08-23 | Human Genome Sciences, Inc. | Pharmaceutical Formulation and Process |
| US7300773B2 (en) | 2004-08-27 | 2007-11-27 | Wyeth Research Ireland Limited | Production of TNFR-Ig |
| WO2006122187A2 (en) | 2005-05-10 | 2006-11-16 | Biogen Idec Ma Inc. | Treating and evaluating inflammatory disorders |
| CN101237890A (zh) | 2005-06-10 | 2008-08-06 | 中外制药株式会社 | 含有葡甲胺的蛋白质制剂的稳定剂及其利用 |
| TW200738261A (en) | 2005-12-20 | 2007-10-16 | Bristol Myers Squibb Co | Stable protein formulations |
| JP5405122B2 (ja) | 2005-12-21 | 2014-02-05 | ワイス・エルエルシー | 低粘度のタンパク質製剤およびその用途 |
| JP2009525986A (ja) | 2006-02-03 | 2009-07-16 | メディミューン，エルエルシー | タンパク質製剤 |
| EA015992B1 (ru) | 2006-03-17 | 2012-01-30 | Байоджен Айдек Эмэй Инк. | Стабилизированное антитело и многовалентная антигенсвязывающая молекула на его основе, способы получения и использования вышеназванного стабилизированного антитела |
| CA2649538C (en) | 2006-04-21 | 2014-06-03 | Yatin Gokarn | Buffering agents for biopharmaceutical formulations |
| CA2665567C (en) | 2006-10-06 | 2012-07-03 | Amgen Inc. | Stable formulations |
| US7705132B2 (en) | 2006-10-20 | 2010-04-27 | Amgen Inc. | Stable polypeptide formulations |
| MX2009004519A (es) | 2006-11-03 | 2009-05-12 | Wyeth Corp | Sustancias que inhiben la glucolisis en un cultivo de celulas. |
| EP2129401B8 (en) | 2006-12-21 | 2020-01-15 | Amgen Inc. | Stable buffered formulations containing polypeptides |
| US7691980B2 (en) | 2007-01-09 | 2010-04-06 | Bio-Rad Laboratories, Inc. | Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers |
| CA2679941C (en) | 2007-03-02 | 2016-09-20 | Wyeth | Use of copper and glutamate in cell culture for production of polypeptides |
| EP2014760A1 (en) | 2007-06-13 | 2009-01-14 | CMC Biopharmaceuticals A/S | A method for producing a biopolymer (e.g. polypeptide) in a continuous fermentation process |
| CA2690382A1 (en) | 2007-06-14 | 2008-12-24 | Biogen Idec Ma Inc. | Antibody formulations |
| US8420081B2 (en) | 2007-11-30 | 2013-04-16 | Abbvie, Inc. | Antibody formulations and methods of making same |
| JP2011514895A (ja) * | 2008-02-29 | 2011-05-12 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 精製免疫グロブリン融合タンパク質およびその精製方法 |
| US9238810B2 (en) * | 2008-06-05 | 2016-01-19 | Affibody Ab | Polypeptide |
| WO2011015926A1 (en) * | 2009-08-03 | 2011-02-10 | Avesthagen Limited | A process of fermentation, purification and production of recombinant soluble tumour necrosis factor alfa receptor (tnfr) - human igg fc fusion protein |
| US8536316B2 (en) | 2009-08-07 | 2013-09-17 | Emd Millipore Corporation | Methods for purifying a target protein from one or more impurities in a sample |
| MX355650B (es) | 2009-08-11 | 2018-04-26 | Genentech Inc | Produccion de proteinas en medios de cultivo de celulas libres de glutamina. |
| WO2011049798A1 (en) * | 2009-10-20 | 2011-04-28 | Merck Sharp & Dohme Corp. | Use of mixed mode chromatography for the capture and purification of basic antibody products |
| EP2516467A2 (en) | 2009-12-23 | 2012-10-31 | Emergent Product Development Seattle, LLC | Compositions comprising tnf-alpha and il-6 antagonists and methods of use thereof |
| AU2011246503B2 (en) | 2010-04-26 | 2013-09-26 | Novartis Ag | Improved cell culture medium |
| RU2600847C2 (ru) * | 2010-05-10 | 2016-10-27 | Интас Биофармасьютикалс Лимитед | Жидкий состав полипептидов, содержащих fc-домен иммуноглобулина |
| EP2598167B1 (en) | 2010-07-30 | 2015-04-01 | Arecor Limited | Stabilized aqueous antibody compositions |
| EP2606119A1 (en) | 2010-08-20 | 2013-06-26 | Wyeth LLC | Cell culture of growth factor-free adapted cells |
| KR20130101034A (ko) | 2010-08-31 | 2013-09-12 | 프리슬랜드 브랜즈 비브이 | 진핵 세포를 위한 배양 배지 |
| BR112013008738B1 (pt) * | 2010-10-11 | 2017-12-19 | Abbvie Bahamas Ltd. | Method for purification of a protein |
| RU2614257C2 (ru) | 2011-04-20 | 2017-03-24 | Сандоз Аг | СТАБИЛЬНЫЕ ЖИДКИЕ ФАРМАЦЕВТИЧЕСКИЕ ПРЕПАРАТЫ СЛИТОГО БЕЛКА TNFR:Fc |
| UY34105A (es) | 2011-06-03 | 2012-07-31 | Lg Life Sciences Ltd | Formulación líquida estable de etanercept |
| SI2726600T1 (sl) | 2011-07-01 | 2017-07-31 | Amgen Inc. | Sesalska celična kultura |
| EA026226B1 (ru) | 2011-07-01 | 2017-03-31 | Байоджен Айдек Ма Инк. | Не содержащие аргинина композиции слитого fc-полипептида и способы их применения |
| JP6280499B2 (ja) * | 2011-07-08 | 2018-02-14 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | Ｆｃ融合タンパク質の精製方法 |
| ES2651483T3 (es) * | 2011-08-17 | 2018-01-26 | Ares Trading S.A. | Método para preparar la forma activa de la proteína de fusión TNRF-Fc |
| US10485869B2 (en) * | 2011-10-18 | 2019-11-26 | Coherus Biosciences, Inc. | Etanercept formulations stabilized with meglumine |
| AU2012326170B2 (en) * | 2011-10-18 | 2016-12-22 | Coherus Biosciences, Inc. | Etanercept formulations stabilized with metal ions |
| WO2014011629A1 (en) * | 2012-07-09 | 2014-01-16 | Coherus Biosciences, Inc. | Stable aqueous formulations of etanercept |
| KR102250937B1 (ko) * | 2012-09-11 | 2021-05-12 | 코히러스 바이오사이언시즈, 인코포레이티드 | 고순도 및 탁월한 수율의 정확하게 폴딩된 에타너셉트 |
| CA2916836C (en) * | 2014-07-31 | 2017-12-12 | Mtt Innovation Incorporated | Numerical approaches for free-form lensing: area parameterization free-form lensing |
| US20160108634A1 (en) * | 2014-10-16 | 2016-04-21 | Ronald Uphold | Pool Cover Hanger Device |
-
2013
- 2013-09-10 KR KR1020207019733A patent/KR102250937B1/ko not_active Expired - Fee Related
- 2013-09-10 RS RS20180095A patent/RS57013B1/sr unknown
- 2013-09-10 EP EP13838016.7A patent/EP2895188B1/en active Active
- 2013-09-10 LT LTEP13838016.7T patent/LT2895188T/lt unknown
- 2013-09-10 PL PL13838016T patent/PL2895188T3/pl unknown
- 2013-09-10 DK DK13838016.7T patent/DK2895188T3/en active
- 2013-09-10 SI SI201330936T patent/SI2895188T1/en unknown
- 2013-09-10 PE PE2015000316A patent/PE20150996A1/es unknown
- 2013-09-10 IN IN452KON2015 patent/IN2015KN00452A/en unknown
- 2013-09-10 BR BR112015005161A patent/BR112015005161A2/pt not_active Application Discontinuation
- 2013-09-10 CA CA2882551A patent/CA2882551A1/en active Pending
- 2013-09-10 SM SM20180163T patent/SMT201800163T1/it unknown
- 2013-09-10 PE PE2019002512A patent/PE20200607A1/es unknown
- 2013-09-10 CN CN201380058650.5A patent/CN104902914B/zh not_active Expired - Fee Related
- 2013-09-10 WO PCT/US2013/058994 patent/WO2014043103A1/en not_active Ceased
- 2013-09-10 AU AU2013315750A patent/AU2013315750B9/en not_active Ceased
- 2013-09-10 ES ES13838016.7T patent/ES2657377T3/es active Active
- 2013-09-10 PT PT138380167T patent/PT2895188T/pt unknown
- 2013-09-10 EA EA201590542A patent/EA031324B1/ru unknown
- 2013-09-10 MX MX2015003090A patent/MX360044B/es active IP Right Grant
- 2013-09-10 JP JP2015531311A patent/JP2015533797A/ja active Pending
- 2013-09-10 SG SG11201501460RA patent/SG11201501460RA/en unknown
- 2013-09-10 CN CN201811633164.2A patent/CN110051823A/zh active Pending
- 2013-09-10 HU HUE13838016A patent/HUE036524T2/hu unknown
- 2013-09-10 KR KR1020157009386A patent/KR102133699B1/ko not_active Expired - Fee Related
- 2013-09-10 HR HRP20180182TT patent/HRP20180182T1/hr unknown
- 2013-09-11 TW TW106136921A patent/TWI716649B/zh not_active IP Right Cessation
- 2013-09-11 AR ARP130103250A patent/AR092532A1/es not_active Application Discontinuation
- 2013-09-11 US US14/023,736 patent/US20140072560A1/en not_active Abandoned
- 2013-09-11 TW TW102132831A patent/TWI609877B/zh not_active IP Right Cessation
-
2014
- 2014-03-13 NO NO14719160A patent/NO2972131T3/no unknown
-
2015
- 2015-02-19 IL IL237311A patent/IL237311B/en active IP Right Grant
- 2015-03-06 CL CL2015000572A patent/CL2015000572A1/es unknown
- 2015-03-10 MX MX2018012749A patent/MX2018012749A/es unknown
- 2015-03-10 DO DO2015000055A patent/DOP2015000055A/es unknown
- 2015-04-07 CO CO15076746A patent/CO7400876A2/es unknown
- 2015-04-10 EC ECIEPI201514138A patent/ECSP15014138A/es unknown
-
2017
- 2017-09-29 US US15/720,291 patent/US11001627B2/en not_active Expired - Fee Related
-
2018
- 2018-02-13 CY CY20181100172T patent/CY1120062T1/el unknown
- 2018-10-10 AU AU2018247244A patent/AU2018247244B2/en not_active Ceased
- 2018-10-11 JP JP2018192476A patent/JP6913066B2/ja not_active Expired - Fee Related
-
2019
- 2019-06-17 US US16/443,721 patent/US10954295B2/en not_active Expired - Fee Related
- 2019-06-17 US US16/443,514 patent/US10954293B2/en not_active Expired - Fee Related
- 2019-06-17 US US16/443,594 patent/US10954294B2/en not_active Expired - Fee Related
- 2019-06-17 US US16/443,688 patent/US10947306B2/en not_active Expired - Fee Related
- 2019-06-18 IL IL267452A patent/IL267452B/en active IP Right Grant
-
2021
- 2021-02-22 JP JP2021025939A patent/JP2021100929A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2015000055A (es) | Etanercept correctamente plegado de alta pureza y excelente rendimiento | |
| CL2020000428A1 (es) | Preparación de exosomas terapéuticos mediante el uso de proteínas de membrana. | |
| CY1125392T1 (el) | Συνθεσεις και μεθοδοι γλυζυλιωσης πρωτεϊνων | |
| AR092050A1 (es) | Proteinas de fusion de anticuerpos e interleuquina 10 y usos de las mismas | |
| CR20140175A (es) | Compuestos y métodos para mejorar las respuestas inmunitarias innatas | |
| EA201391597A1 (ru) | Толерогенные синтетические наноносители, уменьшающие иммунный ответ на терапевтические белки | |
| EA201890817A1 (ru) | Кристаллические формы бета-никотинамида мононуклеотида | |
| CY1119576T1 (el) | Ν-ακυλ-(3-υποκατεστημενες)-(8-υποκατεστημενες)-5,6-διϋδρο-[1,2,4]τριαζολο[4,3-α]πυραζινες ως επιλεκτικοι ανταγωνιστες του υποδοχεα νκ-3, φαρμακευτικη συνθεση, μεθοδοι για χρηση σε διαμεσολαβουμενες απο τον υποδοχεα νκ-3 διαταραχες | |
| EA201791507A1 (ru) | Пирроло- и пиразолопиримидины в качестве ингибиторов убиквитин- специфичной протеазы 7 | |
| EA201690093A1 (ru) | Производные пирроло[3,2-d]пиримидина для лечения вирусных инфекций и других заболеваний | |
| BR112015022191A2 (pt) | compostos heteroarila, seu uso e composição que os compreende | |
| EA201690898A1 (ru) | Способы лечения таупатии | |
| CR20160222U (es) | Formas solidas de acido { [ -(3- clorofenil) -3- hidroxipiridin -2-carbonil] amino} acetico, composiciones, y usos de las mismas | |
| EA201391632A1 (ru) | Аминокислотные последовательности, направленные против il-17a, il-17f и/или il-17a/f, и содержащие их полипептиды | |
| BR112015013525A2 (pt) | método para produção de uma proteína de fusão, bem como composição compreendendo uma proteína de fusão | |
| EA201391719A1 (ru) | Хиназолиновые производные для лечения вирусных инфекций и дальнейших заболеваний | |
| EA201591591A1 (ru) | Соединения карбазола, применяемые в качестве ингибиторов бромодомена | |
| EA201591501A1 (ru) | Терапевтические средства на основе csf-1 | |
| CO6491045A2 (es) | Composiciones de proteina f de virus sincitial respiratorio (rsv) y metodos para producir las mismas | |
| DOP2013000235A (es) | Proteínas de fusión y vacunas de combinación que comprenden proteína e y pilina a de haemophilus influenzae. | |
| EA201590667A1 (ru) | Ациламинопиримидиновые производные для лечения вирусных инфекций и других заболеваний | |
| MX2021015825A (es) | Formulaciones de anticuerpos estables acuosas. | |
| EA201391515A1 (ru) | Инактивированная вакцина вируса денге | |
| MX2019002915A (es) | Derivado de ?-aminoacido triciclico fusionado, metodo de preparacion, y su uso medico del mismo. | |
| MX2017005243A (es) | Reducción de la viscosidad de formulaciones farmacéuticas. |